Q3 2023 EPS Estimates for Nemaura Medical Inc. Lowered by HC Wainwright (NASDAQ:NMRD)

Nemaura Medical Inc. (NASDAQ:NMRDGet Rating) – Research analysts at HC Wainwright cut their Q3 2023 earnings per share (EPS) estimates for shares of Nemaura Medical in a research report issued to clients and investors on Monday, November 21st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.18) per share for the quarter, down from their prior estimate of ($0.16). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Nemaura Medical’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Nemaura Medical’s Q4 2023 earnings at ($0.17) EPS, FY2023 earnings at ($0.69) EPS, Q1 2024 earnings at ($0.15) EPS, Q2 2024 earnings at ($0.14) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.12) EPS and FY2024 earnings at ($0.55) EPS.

Nemaura Medical Price Performance

NMRD stock opened at $2.00 on Thursday. Nemaura Medical has a 1-year low of $1.50 and a 1-year high of $5.94. The business’s 50 day simple moving average is $2.19 and its 200 day simple moving average is $2.29.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Nemaura Medical stock. ARS Investment Partners LLC boosted its position in Nemaura Medical Inc. (NASDAQ:NMRDGet Rating) by 12.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 86,876 shares of the company’s stock after purchasing an additional 9,849 shares during the quarter. ARS Investment Partners LLC owned about 0.36% of Nemaura Medical worth $223,000 at the end of the most recent reporting period. 3.47% of the stock is currently owned by institutional investors and hedge funds.

About Nemaura Medical

(Get Rating)

Nemaura Medical Inc, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs.

Further Reading

Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.